RapidPulse announced today that it raised $10.5 million in a financing round led by Syntheon and Santé Ventures.
Epidarex Capital, Hatteras Venture Partners and Broadview Ventures also joined the round. It brings RapidPulse’s total funding to more than $25 million.
Miami-based RapidPulse develops a novel cyclic aspiration system to treat ischemic stroke. It plans to use funding proceeds to further advance its RapidPulse system through expanded clinical evaluation. In turn, it expects this to further the development and move it toward FDA approval.
“RapidPulse has built an excellent team and taken great strides in developing our technology and system architecture; we’ve had three seminal patents issued to protect our intellectual property and we’ve received excellent feedback from some of the leading ischemic stroke physicians,” said Sean McBrayer, who serves as the CEO of RapidPulse as well as CEO of Syntheon.